Published in J Biol Chem on September 21, 2010
Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov (2014) 1.86
Biosynthesis of the Pseudomonas aeruginosa Extracellular Polysaccharides, Alginate, Pel, and Psl. Front Microbiol (2011) 1.84
Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol (2012) 1.26
Structure of the cytoplasmic region of PelD, a degenerate diguanylate cyclase receptor that regulates exopolysaccharide production in Pseudomonas aeruginosa. J Biol Chem (2012) 1.11
Survey of phosphorylation near drug binding sites in the Protein Data Bank (PDB) and their effects. Proteins (2014) 0.88
Structures of the PelD cyclic diguanylate effector involved in pellicle formation in Pseudomonas aeruginosa PAO1. J Biol Chem (2012) 0.85
Molecular architecture of photoreceptor phosphodiesterase elucidated by chemical cross-linking and integrative modeling. J Mol Biol (2014) 0.84
Distinct patterns of compartmentalization and proteolytic stability of PDE6C mutants linked to achromatopsia. Mol Cell Neurosci (2014) 0.77
Cyclic nucleotide binding and structural changes in the isolated GAF domain of Anabaena adenylyl cyclase, CyaB2. PeerJ (2015) 0.76
Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr (1998) 169.28
Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A (1991) 119.63
PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr (2002) 53.61
Macromolecular TLS refinement in REFMAC at moderate resolutions. Methods Enzymol (2003) 9.69
Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med (2005) 9.27
Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev (2006) 6.75
Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem (2007) 5.62
The GAF domain: an evolutionary link between diverse phototransducing proteins. Trends Biochem Sci (1997) 4.10
Overview of PDEs and their regulation. Circ Res (2007) 3.42
Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther (2005) 3.27
Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today (2005) 3.20
Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov (2006) 2.10
The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding. Proc Natl Acad Sci U S A (2002) 2.10
Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet (2005) 2.02
PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J (2003) 1.56
Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov (2002) 1.55
Properties and functions of GAF domains in cyclic nucleotide phosphodiesterases and other proteins. Mol Pharmacol (2004) 1.42
Crystal structure of the tandem GAF domains from a cyanobacterial adenylyl cyclase: modes of ligand binding and dimerization. Proc Natl Acad Sci U S A (2005) 1.40
Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct. Proc Natl Acad Sci U S A (2009) 1.30
Improving memory: a role for phosphodiesterases. Curr Pharm Des (2006) 1.22
The structure of the GAF A domain from phosphodiesterase 6C reveals determinants of cGMP binding, a conserved binding surface, and a large cGMP-dependent conformational change. J Biol Chem (2008) 1.15
Molecular determinants for cyclic nucleotide binding to the regulatory domains of phosphodiesterase 2A. J Biol Chem (2004) 1.12
Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation. Biochem J (1998) 1.11
Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation. J Biol Chem (2005) 1.06
cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11. J Biol Chem (2005) 1.04
Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity. J Biol Chem (2002) 1.01
Solution structure of the cGMP binding GAF domain from phosphodiesterase 5: insights into nucleotide specificity, dimerization, and cGMP-dependent conformational change. J Biol Chem (2008) 1.01
Specific cGMP binding by the cGMP binding domains of cGMP-binding cGMP specific phosphodiesterase. Cell Signal (2002) 1.00
Crystal structure of the GAF-B domain from human phosphodiesterase 10A complexed with its ligand, cAMP. J Biol Chem (2008) 0.99
Direct allosteric regulation between the GAF domain and catalytic domain of photoreceptor phosphodiesterase PDE6. J Biol Chem (2008) 0.90
Structural and biochemical aspects of tandem GAF domains. Handb Exp Pharmacol (2009) 0.86
Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme. Cell Signal (2009) 0.83
The properties of phosphodiesterase 11A4 GAF domains are regulated by modifications in its N-terminal domain. FEBS J (2008) 0.80
Functional chimeras of the phosphodiesterase 5 and 10 tandem GAF domains. J Biol Chem (2008) 0.77
Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell (2012) 5.71
Structural and biochemical studies of ALIX/AIP1 and its role in retrovirus budding. Cell (2007) 3.06
The 1.9 A structure of a proteasome-11S activator complex and implications for proteasome-PAN/PA700 interactions. Mol Cell (2005) 2.68
Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell (2011) 2.58
The crystal structure of Mtr4 reveals a novel arch domain required for rRNA processing. EMBO J (2010) 2.25
Familial Parkinson's disease-associated L166P mutation disrupts DJ-1 protein folding and function. J Biol Chem (2003) 2.21
Structure and ubiquitin binding of the ubiquitin-interacting motif. J Biol Chem (2003) 2.19
The Fas-FADD death domain complex structure unravels signalling by receptor clustering. Nature (2008) 2.11
AlgK is a TPR-containing protein and the periplasmic component of a novel exopolysaccharide secretin. Structure (2010) 1.97
Structures of the N-terminal and middle domains of E. coli Hsp90 and conformation changes upon ADP binding. Structure (2005) 1.91
Cyclic GMP from the surrounding somatic cells regulates cyclic AMP and meiosis in the mouse oocyte. Development (2009) 1.78
Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein. J Mol Biol (2007) 1.78
Time-dependent, protein-directed growth of gold nanoparticles within a single crystal of lysozyme. Nat Nanotechnol (2011) 1.77
Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation. J Am Chem Soc (2009) 1.75
Crystal structure of DJ-1/RS and implication on familial Parkinson's disease. FEBS Lett (2003) 1.73
Structure of the mid-region of tropomyosin: bending and binding sites for actin. Proc Natl Acad Sci U S A (2005) 1.72
Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes. Proc Natl Acad Sci U S A (2002) 1.72
High-resolution design of a protein loop. Proc Natl Acad Sci U S A (2007) 1.68
Rationally tuning the reduction potential of a single cupredoxin beyond the natural range. Nature (2009) 1.68
Rational design of a structural and functional nitric oxide reductase. Nature (2009) 1.60
Structural studies of a bacterial condensin complex reveal ATP-dependent disruption of intersubunit interactions. Cell (2009) 1.58
A dimerized coiled-coil domain and an adjoining part of geminin interact with two sites on Cdt1 for replication inhibition. Mol Cell (2004) 1.48
Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity. J Biol Chem (2003) 1.47
Implications for viral capsid assembly from crystal structures of HIV-1 Gag(1-278) and CA(N)(133-278). Biochemistry (2006) 1.41
Structural basis for ubiquitin recognition by the human ESCRT-II EAP45 GLUE domain. Nat Struct Mol Biol (2006) 1.41
The refined crystal structure of an eel pout type III antifreeze protein RD1 at 0.62-A resolution reveals structural microheterogeneity of protein and solvation. Biophys J (2003) 1.36
Structure of a Blm10 complex reveals common mechanisms for proteasome binding and gate opening. Mol Cell (2010) 1.36
The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis. Biochemistry (2003) 1.30
Roles of glutamates and metal ions in a rationally designed nitric oxide reductase based on myoglobin. Proc Natl Acad Sci U S A (2010) 1.29
Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. J Biol Chem (2006) 1.29
Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7. J Biol Chem (2005) 1.25
Structural insight into substrate specificity of phosphodiesterase 10. Proc Natl Acad Sci U S A (2007) 1.22
Crystal structure of the Leishmania major phosphodiesterase LmjPDEB1 and insight into the design of the parasite-selective inhibitors. Mol Microbiol (2007) 1.20
Crystal structures of the BlaI repressor from Staphylococcus aureus and its complex with DNA: insights into transcriptional regulation of the bla and mec operons. J Bacteriol (2005) 1.19
Structural models for interactions between the 20S proteasome and its PAN/19S activators. J Biol Chem (2009) 1.17
Crystal structure and RNA binding of the Tex protein from Pseudomonas aeruginosa. J Mol Biol (2008) 1.15
Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding. Proc Natl Acad Sci U S A (2004) 1.14
Essential role of the B23/NPM core domain in regulating ARF binding and B23 stability. J Biol Chem (2006) 1.13
Structure of the cytoplasmic region of PelD, a degenerate diguanylate cyclase receptor that regulates exopolysaccharide production in Pseudomonas aeruginosa. J Biol Chem (2012) 1.11
Structural basis for alginate secretion across the bacterial outer membrane. Proc Natl Acad Sci U S A (2011) 1.11
Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. Structure (2003) 1.10
Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite. Future Med Chem (2011) 1.10
Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity. Biochemistry (2008) 1.09
Crystal structure of the pyocyanin biosynthetic protein PhzS. Biochemistry (2008) 1.08
Crystal structure of the [Mg2+-(chromomycin A3)2]-d(TTGGCCAA)2 complex reveals GGCC binding specificity of the drug dimer chelated by a metal ion. Nucleic Acids Res (2004) 1.08
Crystal structure of Haemophilus influenzae NadR protein. A bifunctional enzyme endowed with NMN adenyltransferase and ribosylnicotinimide kinase activities. J Biol Chem (2002) 1.07
Identification and structural characterization of the ALIX-binding late domains of simian immunodeficiency virus SIVmac239 and SIVagmTan-1. J Virol (2010) 1.06
p53 Oligomerization is essential for its C-terminal lysine acetylation. J Biol Chem (2008) 1.06
The peptide-receptive transition state of MHC class I molecules: insight from structure and molecular dynamics. J Immunol (2012) 1.05
Characterization of two potentially universal turn motifs that shape the repeated five-residues fold--crystal structure of a lumenal pentapeptide repeat protein from Cyanothece 51142. Protein Sci (2006) 1.05
Structural and functional analysis of the pyocyanin biosynthetic protein PhzM from Pseudomonas aeruginosa. Biochemistry (2007) 1.04
Therapeutic potential of phosphodiesterase inhibitors in parasitic diseases. Handb Exp Pharmacol (2011) 1.03
Structural insights into membrane targeting by the flagellar calcium-binding protein (FCaBP), a myristoylated and palmitoylated calcium sensor in Trypanosoma cruzi. J Biol Chem (2008) 1.02
Alternative conformations of the archaeal Nop56/58-fibrillarin complex imply flexibility in box C/D RNPs. J Mol Biol (2007) 1.02
Computer-based redesign of a beta sandwich protein suggests that extensive negative design is not required for de novo beta sheet design. Structure (2008) 1.01
Impaired acid catalysis by mutation of a protein loop hinge residue in a YopH mutant revealed by crystal structures. J Am Chem Soc (2009) 1.01
Profound asymmetry in the structure of the cAMP-free cAMP Receptor Protein (CRP) from Mycobacterium tuberculosis. J Biol Chem (2009) 1.01
Crystal structure of human kynurenine aminotransferase II. J Biol Chem (2007) 1.00
Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors. Biochem J (2007) 1.00
A designed functional metalloenzyme that reduces O2 to H2O with over one thousand turnovers. Angew Chem Int Ed Engl (2012) 1.00
Substrate specificity and structure of human aminoadipate aminotransferase/kynurenine aminotransferase II. Biosci Rep (2008) 0.99
Biochemical and structural properties of mouse kynurenine aminotransferase III. Mol Cell Biol (2008) 0.98
Structural mechanism for inactivation and activation of CAD/DFF40 in the apoptotic pathway. Mol Cell (2004) 0.98
Structure of the Spt16 middle domain reveals functional features of the histone chaperone FACT. J Biol Chem (2013) 0.98
NSP-Cas protein structures reveal a promiscuous interaction module in cell signaling. Nat Struct Mol Biol (2011) 0.97
Structure of ERK2 bound to PEA-15 reveals a mechanism for rapid release of activated MAPK. Nat Commun (2013) 0.96
Visualizing key hinges and a potential major source of compliance in the lever arm of myosin. Proc Natl Acad Sci U S A (2010) 0.96
Crystal structure of actinomycin D bound to the CTG triplet repeat sequences linked to neurological diseases. Nucleic Acids Res (2002) 0.96
The structure- and metal-dependent activity of Escherichia coli PgaB provides insight into the partial de-N-acetylation of poly-β-1,6-N-acetyl-D-glucosamine. J Biol Chem (2012) 0.96
Crystal structures of Aedes aegypti alanine glyoxylate aminotransferase. J Biol Chem (2006) 0.96
Crystal structure of the oxygen-dependant coproporphyrinogen oxidase (Hem13p) of Saccharomyces cerevisiae. J Biol Chem (2004) 0.96
Introducing a 2-His-1-Glu nonheme iron center into myoglobin confers nitric oxide reductase activity. J Am Chem Soc (2010) 0.95
Systematic tuning of heme redox potentials and its effects on O2 reduction rates in a designed oxidase in myoglobin. J Am Chem Soc (2014) 0.95
Beamline X29: a novel undulator source for X-ray crystallography. J Synchrotron Radiat (2006) 0.95
Crystallographic and nuclear magnetic resonance evaluation of the impact of peptide binding to the second PDZ domain of protein tyrosine phosphatase 1E. Biochemistry (2010) 0.95
Identification, structural, and biochemical characterization of a group of large Csn2 proteins involved in CRISPR-mediated bacterial immunity. Proteins (2012) 0.93
Crystal structure of the murine cytomegalovirus MHC-I homolog m144. J Mol Biol (2006) 0.93
Crystal structure and substrate specificity of Drosophila 3,4-dihydroxyphenylalanine decarboxylase. PLoS One (2010) 0.92
Different vaccine vectors delivering the same antigen elicit CD8+ T cell responses with distinct clonotype and epitope specificity. J Immunol (2009) 0.92
Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Mol Pharmacol (2007) 0.92
Structure of the Chlamydia protein CADD reveals a redox enzyme that modulates host cell apoptosis. J Biol Chem (2004) 0.92
Structure of the F-spondin domain of mindin, an integrin ligand and pattern recognition molecule. EMBO J (2009) 0.91
Crystal structures of the S. cerevisiae Spt6 core and C-terminal tandem SH2 domain. J Mol Biol (2011) 0.91
Discovery of novel Trypanosoma brucei phosphodiesterase B1 inhibitors by virtual screening against the unliganded TbrPDEB1 crystal structure. J Med Chem (2013) 0.91
Structure of PqsD, a Pseudomonas quinolone signal biosynthetic enzyme, in complex with anthranilate. Biochemistry (2009) 0.91
Structure of the class IV adenylyl cyclase reveals a novel fold. J Mol Biol (2006) 0.90
The molecular basis for different recognition of substrates by phosphodiesterase families 4 and 10. J Mol Biol (2007) 0.90
A 1.7A structure of Fve, a member of the new fungal immunomodulatory protein family. J Mol Biol (2003) 0.90
Structural insight into the inhibition of human kynurenine aminotransferase I/glutamine transaminase K. J Med Chem (2009) 0.89
Molecular docking of competitive phosphodiesterase inhibitors. Mol Pharmacol (2002) 0.89
Human glutathione-dependent formaldehyde dehydrogenase. Structures of apo, binary, and inhibitory ternary complexes. Biochemistry (2002) 0.89